Elicera Therapeutics AB (publ) announced that it has received a Communication EPC (Notice of Allowance) from the European Patent Office in its European patent application relating to the use of the iTANK[TM] technology in CAR T-cell therapies. The Communication means that the European Patent Office intends to grant the European patent application after the completion of certain formal steps. Once granted, the patent can be kept in force until 2036.